Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer.
Seiler R, Oo HZ, Tortora D, Clausen TM, Wang CK, Kumar G, Pereira MA, Ørum-Madsen MS, Agerbæk MØ, Gustavsson T, Nordmaj MA, Rich JR, Lallous N, Fazli L, Lee SS, Douglas J, Todenhöfer T, Esfandnia S, Battsogt D, Babcook JS, Al-Nakouzi N, Crabb SJ, Moskalev I, Kiss B, Davicioni E, Thalmann GN, Rennie PS, Black PC, Salanti A, Daugaard M. Seiler R, et al. Among authors: crabb sj. Eur Urol. 2017 Jul;72(1):142-150. doi: 10.1016/j.eururo.2017.03.021. Epub 2017 Apr 10. Eur Urol. 2017. PMID: 28408175
Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.
Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Szabados B, Pous AF, Gravis G, Herranz UA, Protheroe A, Ravaud A, Maillet D, Mendez MJ, Suarez C, Linch M, Prendergast A, van Dam PJ, Stanoeva D, Daelemans S, Mariathasan S, Tea JS, Mousa K, Banchereau R, Castellano D. Powles T, et al. Among authors: crabb sj. Nat Med. 2023 Dec;29(12):3271. doi: 10.1038/s41591-023-02312-9. Nat Med. 2023. PMID: 36944799 No abstract available.
A multicentre randomised controlled trial of a guided self-help cognitive behavioural therapy to MANage the impact of hot flushes and night sweats in patients with prostate CANcer undergoing androgen deprivation therapy (MANCAN2).
Crabb S, Morgan A, Hunter MS, Stefanopoulou E, Griffiths G, Richardson A, Fenlon D, Fleure L, Raftery J, Boxall C, Wilding S, Nuttall J, Eminton Z, Tilt E, O'Neill A, Bacon R, Martin J. Crabb S, et al. Trials. 2023 Jul 10;24(1):450. doi: 10.1186/s13063-023-07325-w. Trials. 2023. PMID: 37430353 Free PMC article. Clinical Trial.
Using the AR-V7 biomarker to determine treatment in metastatic castrate resistant prostate cancer, a feasibility randomised control trial, conclusions from the VARIANT trial.
Gravestock P, Clark E, Morton M, Sharma S, Fisher H, Walker J, Wood R, Hancock H, Waugh N, Cooper A, Maier R, Marshall J, Chandler R, Bahl A, Crabb S, Jain S, Pedley I, Jones R, Staffurth J, Heer R. Gravestock P, et al. NIHR Open Res. 2023 Jan 10;2:49. doi: 10.3310/nihropenres.13284.2. eCollection 2022. NIHR Open Res. 2023. PMID: 37035713 Free PMC article.
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study.
Santoni M, Myint ZW, Büttner T, Takeshita H, Okada Y, Lam ET, Gilbert D, Küronya Z, Tural D, Pichler R, Grande E, Crabb SJ, Kemp R, Massari F, Scagliarini S, Iacovelli R, Vau N, Basso U, Maruzzo M, Molina-Cerrillo J, Galli L, Bamias A, De Giorgi U, Zucali PA, Rizzo M, Seront E, Popovic L, Caffo O, Buti S, Kanesvaran R, Kopecky J, Kucharz J, Zeppellini A, Fiala O, Landmesser J, Ansari J, Giannatempo P, Rizzo A, Zabalza IO, Monteiro FSM, Battelli N, Calabrò F, Porta C. Santoni M, et al. Among authors: crabb sj. Cancer Immunol Immunother. 2023 Sep;72(9):2961-2970. doi: 10.1007/s00262-023-03469-5. Epub 2023 May 29. Cancer Immunol Immunother. 2023. PMID: 37248424 Free PMC article.
Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).
Necchi A, Sonpavde G, Lo Vullo S, Giardiello D, Bamias A, Crabb SJ, Harshman LC, Bellmunt J, De Giorgi U, Sternberg CN, Cerbone L, Ladoire S, Wong YN, Yu EY, Chowdhury S, Niegisch G, Srinivas S, Vaishampayan UN, Pal SK, Agarwal N, Alva A, Baniel J, Golshayan AR, Morales-Barrera R, Bowles DW, Milowsky MI, Theodore C, Berthold DR, Daugaard G, Sridhar SS, Powles T, Rosenberg JE, Galsky MD, Mariani L; RISC Investigators. Necchi A, et al. Among authors: crabb sj. Eur Urol. 2017 Feb;71(2):281-289. doi: 10.1016/j.eururo.2016.09.042. Epub 2016 Oct 8. Eur Urol. 2017. PMID: 27726966 Free PMC article.
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.
Seiler R, Ashab HAD, Erho N, van Rhijn BWG, Winters B, Douglas J, Van Kessel KE, Fransen van de Putte EE, Sommerlad M, Wang NQ, Choeurng V, Gibb EA, Palmer-Aronsten B, Lam LL, Buerki C, Davicioni E, Sjödahl G, Kardos J, Hoadley KA, Lerner SP, McConkey DJ, Choi W, Kim WY, Kiss B, Thalmann GN, Todenhöfer T, Crabb SJ, North S, Zwarthoff EC, Boormans JL, Wright J, Dall'Era M, van der Heijden MS, Black PC. Seiler R, et al. Among authors: crabb sj. Eur Urol. 2017 Oct;72(4):544-554. doi: 10.1016/j.eururo.2017.03.030. Epub 2017 Apr 5. Eur Urol. 2017. PMID: 28390739
124 results